These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15330347)

  • 21. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
    Meng Y; Squires H; Stevens JW; Simpson E; Harnan S; Thomas S; Michaels J; Stansby G; O'Donnell ME
    Angiology; 2014 Mar; 65(3):190-7. PubMed ID: 23378195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
    Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
    Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cilostazol: treatment of intermittent claudication.
    Reilly MP; Mohler ER
    Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
    Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
    Br J Surg; 2013 Dec; 100(13):1838-9. PubMed ID: 24227373
    [No Abstract]   [Full Text] [Related]  

  • 25. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
    Lee TM; Su SF; Hwang JJ; Tseng CD; Chen MF; Lee YT; Wang SS
    Atherosclerosis; 2001 Oct; 158(2):471-6. PubMed ID: 11583728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
    Squires H; Simpson E; Meng Y; Harnan S; Stevens J; Wong R; Thomas S; Michaels J; Stansby G
    Health Technol Assess; 2011 Dec; 15(40):1-210. PubMed ID: 22142554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cilostazol: a review of its use in intermittent claudication.
    Chapman TM; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(2):117-38. PubMed ID: 14727939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of cilostazol in the treatment of intermittent claudication.
    Barnett AH; Bradbury AW; Brittenden J; Crichton B; Donnelly R; Homer-Vanniasinkam S; Mikhailidis DP; Stansby G
    Curr Med Res Opin; 2004 Oct; 20(10):1661-70. PubMed ID: 15462700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication.
    de Albuquerque RM; Virgini-Magalhães CE; Lencastre Sicuro F; Bottino DA; Bouskela E
    Angiology; 2008; 59(5):549-58. PubMed ID: 18388031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cilostazol.
    Sorkin EM; Markham A
    Drugs Aging; 1999 Jan; 14(1):63-71; discussion 72-3. PubMed ID: 10069409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients].
    Farkas K; Kolossváry E; Járai Z
    Orv Hetil; 2020 Sep; 161(38):1637-1645. PubMed ID: 32924968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
    J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
    Regensteiner JG; Ware JE; McCarthy WJ; Zhang P; Forbes WP; Heckman J; Hiatt WR
    J Am Geriatr Soc; 2002 Dec; 50(12):1939-46. PubMed ID: 12473004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.
    Strandness DE; Dalman RL; Panian S; Rendell MS; Comp PC; Zhang P; Forbes WP
    Vasc Endovascular Surg; 2002; 36(2):83-91. PubMed ID: 11951094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain.
    Yentes JM; Huisinga JM; Myers SA; Pipinos II; Johanning JM; Stergiou N
    J Appl Biomech; 2012 May; 28(2):184-91. PubMed ID: 22723116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.
    Huisinga JM; Pipinos II; Stergiou N; Johanning JM
    J Appl Biomech; 2010 Aug; 26(3):341-8. PubMed ID: 20841626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cilostazol: improving walking distance in patients with intermittent claudication.
    Collinson DJ; Donnelly R
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):503-9. PubMed ID: 15225110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cilostazol approved for use in intermittent claudication.
    Miller JL
    Am J Health Syst Pharm; 1999 Mar; 56(5):404. PubMed ID: 10096695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.